Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data

Author:

Gröner Albrecht1ORCID

Affiliation:

1. PathoGuard Consult Seeheim‐Jugenheim Germany

Abstract

AbstractThe capacity to remove viruses by Planova filters produced by Asahi Kasei, primarily by small virus‐retentive filters, were compiled from data in peer‐reviewed publications and, partly, publicly available data from presentations at conferences (Planova workshops). Data from more than 100 publications and presentations at conferences covering Planova filters were assessed. The data were grouped according to the different virus filters regarding mean pore sizes and viruses of different sizes for plasma and cell culture derived products. Planova 15N and 20N filters removed parvoviruses below the limit of detection of viruses in the filtrate in approx. 50% of all studies and mean LRFs (log reduction factors) for viruses detected in the filtrate were above 4, demonstrating effective parvovirus reduction. Parvovirus removal capacity increased for Planova BioEX filters as well as for 2 Planova 20N in series. Large viruses as retroviruses (e.g., HIV and MuLV), herpesviruses, flaviviruses and togaviruses were removed effectively by Planova 15N, 20N and BioEX filters and also by Planova 35N filters. Flow interruption, transmembrane pressure, volume and protein concentration per filter area had had no substantial impact on virus removal capacity at manufacturing specification. In conclusion, the incorporation of Planova filters in manufacturing processes of biologicals remove, depending on the filter pore size, small and large viruses from the feed stream reliably. This virus reduction step with an orthogonal mechanism integrated in the manufacturing processes of biologicals, based primarily on size exclusion of viruses, improves the virus safety of these biopharmaceutical products considerably.

Publisher

Wiley

Subject

Biotechnology

Reference49 articles.

1. EMA/CHMP/BWP/706271/2010.Guideline on plasma‐derived medicinal products. European Medicines Agency (EMA); 21 July.2011https://www.ema.europa.eu/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf

2. PPTA.Safety & Quality Standards Programs—International Quality Plasma Program (IQPP) and Quality Standards of Excellence Assurance & Leadership (QSEAL).https://www.pptaglobal.org/safety-quality/standards

3. ICH Q5A(R1).Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Current Step 4 version dated 23 September.1999https://database.ich.org/sites/default/files/Q5A%28R1%29%20Guideline_0.pdf

4. Virus Retentive Filtration.Technical report No. 41 (Revised 2022). Parenteral Drug Association.2022.

5. Virus filtration: A review of current and future practices in bioprocessing

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3